Hepatoprotective effect of fullerenol/doxorubicin nanocomposite in acute treatment of healthy rats
Autor: | Ivana Borišev, Danica Jović, Vladimir B. Pavlović, Aleksandar Djordjevic, Mariana Seke, Danijela Petrovic, Zlatko Rakočević, Branislava Srdjenovic, Milica Labudovic Borovic |
---|---|
Rok vydání: | 2018 |
Předmět: |
Male
0301 basic medicine Clinical Biochemistry macromolecular substances Oxidative phosphorylation Pharmacology Protective Agents medicine.disease_cause Antioxidants Nanocomposites Pathology and Forensic Medicine 03 medical and health sciences In vivo Ultrastructural analysis polycyclic compounds medicine Animals Doxorubicin Rats Wistar Molecular Biology chemistry.chemical_classification Antibiotics Antineoplastic Fullerenol/doxorubicin nanocomposite biology Superoxide Dismutase Chemistry organic chemicals technology industry and agriculture qRT-PCR Catalase Rats 3. Good health carbohydrates (lipids) Oxidative Stress 030104 developmental biology Enzyme Liver Drug delivery biology.protein Fullerenes AFM Nanocarriers Oxidative stress medicine.drug |
Zdroj: | Experimental and Molecular Pathology |
ISSN: | 0014-4800 |
Popis: | In our recent studies we have designed fullerenol/doxorubicin nanocomposite (FNP/DOX) as the new drug nanocarrier. This research has demonstrated that this novel nanocomposite has had better implications on the liver tissue in vivo (Wistar rats treated intraperitoneally), than treatment based only on DOX. FNP/DOX has been characterised by DLS, TEM and AFM measurements which have shown that DOX loaded onto FNP did not influence fullerenol nanoparticle's size. FNP/DOX affected oxidative status in blood causing a significant decrease of catalase and SOD activity in comparison to DOX, implicating the reduction in oxidative stress. qRT-PCR results on the mRNA level of antioxidative enzymes (catalase and MnSOD) revealed that the effect of oxidative stress is significantly reduced by the treatment with FNP/DOX (p |
Databáze: | OpenAIRE |
Externí odkaz: |